January 28, 2017
Swedish Vicore Pharma’s IPF candidate C21 becomes orphan drug in US
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
January 27, 2017
Roche cancer drug taking bite out of Bristol’s Opdivo
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
January 27, 2017
Theradiag and its South Korean partners get financial support for rectal cancer study
Theradiag and its South Korean partners, Professor Chang-sik Yu and his team at Asan Medical Center and CbsBioscience will receive €1.3 million financial support from Eurostars program for its Pioneer collaborative project undertaken by its Prestizia molecular biology platform.
January 27, 2017
French Poxel exectedly falls short on revenue in Q4 2016
French drugmaker focused on diabetes treatments Poxel, said it expectedly did not generate meaningful revenues in the fourth quarter of 2016, but it is on track for developing two of its programs.
January 27, 2017
The Vetoquinol Goup sales 4.3% up in 2016
The Vetoquinol Group has reported sales of €350.3 million for 2016, representing like-for-like growth of 4.3%.
January 27, 2017
Beximco 16% sales rise drives profit up for the half year
Beximco Pharmaceuticals has posted earnings of $1,113,722, for the second half of 2016, compared to $944,662 to the same period last year.
January 27, 2017
Stallergenes reports positive results for a p3 clinical study of allergic rhinitis in children
Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, has reported positive topline results for a phase 3 clinical…
January 26, 2017
Novartis’s eye health division launches IOL
Alcon and a division of Novartis have launched AcrySof IQ PanOptix Toric presbyopia- and astigmatism-correcting intraocular lens (IOL) for patients with pre-existing corneal astigmatism undergoing cataract surgery.
January 26, 2017
Advanced Oncotherapy welcomes Professor Steve Myers and Hans von Celsing as Non-Executive Directors
Advanced Oncotherapy has appointed Professor Steve Myers OBE and Hans von Celsing as Non-Executive Directors. Hans von Celsing will become Senior…
January 26, 2017
UPDATE: Johnson & Johnson buys Actelion for $30 billion
Johnson & Johnson said on Wednesday it will buy a Switzerland-based pharmaceutical company Actelion for $30 billion.